# EDGAR Filing Document

**Accession Number:** 0001944285
**File Stem:** 0000894189-26-001081
**Filing Date:** 2026-1
**Character Count:** 29611
**Document Hash:** 44c6a104f4d2cb7c365b4233d9f73f2c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000894189-26-001081.hdr.sgml**: 20260121

**ACCESSION NUMBER**: 0000894189-26-001081

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251130

**FILED AS OF DATE**: 20260121

**DATE AS OF CHANGE**: 20260121

**PERIOD START**: 20260228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tema ETF Trust
- **CENTRAL INDEX KEY:** 0001944285

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23823
- **FILM NUMBER:** 26548821

**BUSINESS ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036
- **BUSINESS PHONE:** 3024994928 EXT. 801

**MAIL ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036

## Series and Classes Contracts Data

### Tema Oncology ETF (Series ID: S000078299)

| Class ID   | Class Name        | Ticker Symbol   |
|:---|:---|:---|
| C000239059 | Tema Oncology ETF |  |

## Nport-Ex

---

| | | |
|:---|:---|:---|
| **Tema Oncology ETF** | **Tema Oncology ETF** | **Tema Oncology ETF** |
| **Schedule of Investments** | **Schedule of Investments** | **Schedule of Investments** |
| **November 30, 2025 (Unaudited)** | **November 30, 2025 (Unaudited)** | **November 30, 2025 (Unaudited)** |
| **COMMON STOCKS - 98.6%** | **Shares** | **Value**  |
| **Biotechnology - 67.7% <sup>(a)</sup>** | **Biotechnology - 67.7% <sup>(a)</sup>** | |
| AbbVie, Inc. | 11128 | $2533846 |
| Amgen, Inc. | 4683 | 1617789 |
| AnaptysBio, Inc. <sup>(b)</sup> | 20081 | 836374 |
| Arcellx, Inc. <sup>(b)</sup> | 34948 | 2541069 |
| Arcus Biosciences, Inc. <sup>(b)</sup> | 32129 | 838567 |
| Argenx SE - ADR <sup>(b)</sup> | 1242 | 1132679 |
| Ascentage Pharma Group International - ADR <sup>(b)</sup> | 10385 | 339797 |
| BeOne Medicines Ltd. - ADR <sup>(b)</sup> | 7179 | 2445239 |
| BridgeBio Oncology Therapeutics, Inc. <sup>(b)</sup> | 16658 | 205060 |
| Bridgebio Pharma, Inc. <sup>(b)</sup> | 64050 | 4612241 |
| Celcuity, Inc. <sup>(b)</sup> | 27354 | 2766584 |
| CG oncology, Inc. <sup>(b)</sup> | 32061 | 1437615 |
| Cogent Biosciences, Inc. <sup>(b)</sup> | 101162 | 4068736 |
| Corvus Pharmaceuticals, Inc. <sup>(b)</sup> | 62806 | 575931 |
| Cullinan Therapeutics, Inc. <sup>(b)</sup> | 32857 | 373584 |
| Exelixis, Inc. <sup>(b)</sup> | 68039 | 3005283 |
| Genmab AS - ADR <sup>(b)</sup> | 123261 | 3988726 |
| Gilead Sciences, Inc. | 16672 | 2098004 |
| Halozyme Therapeutics, Inc. <sup>(b)</sup> | 16616 | 1186382 |
| Ideaya Biosciences, Inc. <sup>(b)</sup> | 78791 | 2806535 |
| Immunocore Holdings PLC - ADR <sup>(b)</sup> | 22662 | 895149 |
| Immunome, Inc. <sup>(b)</sup> | 85852 | 1581394 |
| Janux Therapeutics, Inc. <sup>(b)</sup> | 42799 | 1459018 |
| Legend Biotech Corp. - ADR <sup>(b)</sup> | 57858 | 1603245 |
| Nurix Therapeutics, Inc. <sup>(b)</sup> | 68115 | 1204273 |
| Nuvalent, Inc. - Class A <sup>(b)</sup> | 32425 | 3545674 |
| Olema Pharmaceuticals, Inc. <sup>(b)</sup> | 39584 | 1121019 |
| ORIC Pharmaceuticals, Inc. <sup>(b)</sup> | 24783 | 294422 |
| Pyxis Oncology, Inc. <sup>(b)</sup> | 41743 | 216646 |
| Regeneron Pharmaceuticals, Inc. | 1910 | 1490163 |
| Relay Therapeutics, Inc. <sup>(b)</sup> | 99160 | 785347 |
| Replimune Group, Inc. <sup>(b)</sup> | 45584 | 455840 |
| Revolution Medicines, Inc. <sup>(b)</sup> | 102315 | 7956014 |
| Summit Therapeutics, Inc. <sup>(b)</sup> | 85163 | 1523566 |
| Syndax Pharmaceuticals, Inc. <sup>(b)</sup> | 114677 | 2272898 |
| UroGen Pharma Ltd. <sup>(b)</sup> | 53518 | 1541854 |
| Xencor, Inc. <sup>(b)</sup> | 53760 | 931123 |
| Zai Lab Ltd. - ADR <sup>(b)</sup> | 65841 | 1343815 |
| Zymeworks, Inc. <sup>(b)</sup> | 67539 | 1803967 |
|  |  | 71435468 |
| **Health Care Providers & Services - 0.7%** | **Health Care Providers & Services - 0.7%** |  |
| Guardant Health, Inc. <sup>(b)</sup> | 7064 | 765879 |
| **Health Care Technology - 0.3%** | **Health Care Technology - 0.3%** |  |
| Schrodinger, Inc. <sup>(b)</sup> | 17853 | 313499 |
| **Pharmaceuticals - 29.9% <sup>(a)</sup>** | **Pharmaceuticals - 29.9% <sup>(a)</sup>** |  |
| AstraZeneca PLC | 22973 | 4249394 |
| Bristol-Myers Squibb Co. | 50771 | 2497933 |
| Chugai Pharmaceutical Co. Ltd. | 16624 | 891197 |
| Daiichi Sankyo Co. Ltd. | 47798 | 1182366 |
| Eli Lilly & Co. | 5674 | 6102217 |
| Enliven Therapeutics, Inc. <sup>(b)</sup> | 42762 | 923659 |
| HUTCHMED China Ltd. - ADR <sup>(b)</sup> | 43441 | 626419 |
| Johnson & Johnson | 12777 | 2643817 |
| Merck & Co., Inc. | 20974 | 2198704 |
| Novartis AG | 28475 | 3704480 |
| Nuvation Bio, Inc. – Class A <sup>(b)</sup> | 238898 | 1918351 |
| Roche Holding AG - ADR | 88682 | 4241660 |
| Terns Pharmaceuticals, Inc. <sup>(b)</sup> | 14967 | 420722 |
|  |  | 31600919 |
| **TOTAL COMMON STOCKS** (Cost $75,353,960) | **TOTAL COMMON STOCKS** (Cost $75,353,960) | 104115765 |
| **SHORT-TERM INVESTMENTS**<br> ****  | **SHORT-TERM INVESTMENTS**<br> ****  | **SHORT-TERM INVESTMENTS**<br> ****  |
| **MONEY MARKET FUNDS - 1.6%** | **Shares** | **Value**  |
| First American Treasury Obligations Fund - Class X, 3.91% <sup>(c)</sup> | 1672347 | 1672347 |
| **TOTAL MONEY MARKET FUNDS** (Cost $1,672,347) | **TOTAL MONEY MARKET FUNDS** (Cost $1,672,347) | 1672347 |
| **TOTAL INVESTMENTS - 100.2% (**Cost $77,026,307**)** | **TOTAL INVESTMENTS - 100.2% (**Cost $77,026,307**)** | 105788112 |
| Liabilities in Excess of Other Assets - (0.2)% | Liabilities in Excess of Other Assets - (0.2)% | (234797) |
| **TOTAL NET ASSETS - 100.0%** |  | $105553315 |

---

---

| |
|:---|
| Percentages are stated as a percent of net assets. |
| The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |

---

ADR - American Depositary Receipt <br> PLC - Public Limited Company

(a) To the extent that the Fund invests more heavily in particular industries or sectors of the economy, its performance will be especially sensitive to developments that significantly affect those industries or
 sectors.

(b) Non-income producing security.

(c) The rate shown represents the 7-day annualized yield as of November 30, 2025.

------

#### Tema ETF Trust

#### Tema Oncology ETF
Notes to Quarterly Schedule of Investments

November 30, 2025 (Unaudited)

#### Investment Valuation
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs).

The three levels defined by the hierarchy are as follows:

**• Level 1** — Quoted prices in active markets for identical assets that the Fund's have the ability to access.

**• Level 2** — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

**• Level 3** — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of November 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **<u>Level 1</u>** | **<u>Level 2</u>** | **<u>Level 3</u>** | **<u>Total</u>** |
| **Assets** | | | | |
| **Investments:** | | | | |
|  &nbsp;&nbsp;&nbsp;&nbsp;Common Stocks | $104115765 | $– | $– | $104115765 |
|  &nbsp;&nbsp;&nbsp;&nbsp;Money Market Funds | 1672347 | – | – | 1672347 |
| **Total Investments** | $105788112 | $– | $– | $105788112 |
| Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. |

---

---

| |
|:---|
| **Allocation of Portfolio Holdings by Country as of November 30, 2025** |
| (% of Net Assets) |

---

---

| | | |
|:---|:---|:---|
| United States | $83192430 | 78.9% |
| Switzerland | 7946140 | 7.5 |
| United Kingdom | 5144543 | 4.8 |
| Denmark | 3988726 | 3.8 |
| Japan | 2073563 | 1.9 |
| China | 1683612 | 1.6 |
| Netherlands | 1132679 | 1.1 |
| Hong Kong | 626419 | 0.6 |
| Liabilities in Excess of Other Assets | (234797) | (0.2) |
|  | $**105553315** | 100.0<br> **%** |

---

---

| |
|:---|
| **Sector Classification as of November 30, 2025** |
| (% of Net Assets) |

---

---

| | | |
|:---|:---|:---|
| Health Care | $104115765 | 98.6% |
| Money Market Funds | 1672347 | 1.6 |
| Liabilities in Excess of Other Assets | (234797) | (0.2) |
|  | $**105553315** | 100.0<br> **%** |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Tema ETF Trust

- **b. Investment Company Act file number:** 811-23823

- **c. CIK number of Registrant:** 0001944285

- **d. LEI of Registrant:** 549300JKGDXNE2CLUY37

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 200 Vesey Street

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10281

  - **Telephone number:** 3024994928 EXT 801

**Item A.2. Information about the Series.**

- **a. Name of Series:** Tema Oncology ETF

- **b. EDGAR series identifier (if any):** S000078299

- **c. LEI of Series:** 549300N3IU4YD19QLF24

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-02-28

- **b. Date as of which information is reported:** 2025-11-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $105169985.36

**Total Liabilities:** $329486.54

**Net Assets:** $104840498.82

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000239059 | 7.67%                | 7.90%                | 15.51%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-452639.85              | $6111669.25                                |
| Month 2  | $1470801.48              | $4845996.74                                |
| Month 3  | $1519008.11              | $12128819.66                               |

**Designated Index Information**

- **Index Name:** N/A

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                           | Title                                    | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Bristol-Myers Squibb Co        | Bristol-Myers Squibb Co                  | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |     50429 | NS      | $2481106.80   | 2.37%             |  |  |  | No            |                  1 | On Loan: No      |
| CG oncology Inc                | CG oncology Inc                          | CUSIP: 156944100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     31845 | NS      | $1427929.80   | 1.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Cullinan Therapeutics Inc      | Cullinan Therapeutics Inc                | CUSIP: 230031106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     32635 | NS      | $371059.95    | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Enliven Therapeutics Inc       | Enliven Therapeutics Inc                 | CUSIP: 29337E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     42474 | NS      | $917438.40    | 0.88%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson              | Johnson & Johnson                        | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |     12691 | NS      | $2626021.72   | 2.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvation Bio Inc               | Nuvation Bio Inc                         | CUSIP: 67080N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    237284 | NS      | $1905390.52   | 1.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascentage Pharma Group Interna | Ascentage Pharma Group International     | CUSIP: 04390B105<br>LEI: 300300WBVGZIXEF27W64 | Long             | EC               | CORP              | CN        |     10385 | NS      | $339797.20    | 0.32%             |  |  |  | No            |                  1 | On Loan: No      |
| BeOne Medicines Ltd            | BeOne Medicines Ltd                      | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | US        |      7131 | NS      | $2428889.91   | 2.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcellx Inc                    | Arcellx Inc                              | CUSIP: 03940C100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     34712 | NS      | $2523909.52   | 2.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcus Biosciences Inc          | Arcus Biosciences Inc                    | CUSIP: 03969F109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     31913 | NS      | $832929.30    | 0.79%             |  |  |  | No            |                  1 | On Loan: No      |
| BridgeBio Oncology Therapeutic | BridgeBio Oncology Therapeutics Inc      | CUSIP: 107924102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     16546 | NS      | $203681.26    | 0.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Halozyme Therapeutics Inc      | Halozyme Therapeutics Inc                | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |     16504 | NS      | $1178385.60   | 1.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                 | Merck & Co Inc                           | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |     20834 | NS      | $2184028.22   | 2.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                    | Novartis AG                              | CUSIP: N/A<br>LEI: 5493007HIVTX6SY6XD66       | Long             | EC               | CORP              | CH        |     28283 | NS      | $3679501.73   | 3.51%             |  |  |  | No            |                  1 | On Loan: No      |
| Relay Therapeutics Inc         | Relay Therapeutics Inc                   | CUSIP: 75943R102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     98490 | NS      | $780040.80    | 0.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Syndax Pharmaceuticals Inc     | Syndax Pharmaceuticals Inc               | CUSIP: 87164F105<br>LEI: 529900OF94TRHKZVBS87 | Long             | EC               | CORP              | US        |    113903 | NS      | $2257557.46   | 2.15%             |  |  |  | No            |                  1 | On Loan: No      |
| UroGen Pharma Ltd              | UroGen Pharma Ltd                        | CUSIP: N/A<br>LEI: 549300C0YCX7CG2G5D50       | Long             | EC               | CORP              | US        |     53158 | NS      | $1531481.98   | 1.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Cogent Biosciences Inc         | Cogent Biosciences Inc                   | CUSIP: 19240Q201<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    100480 | NS      | $4041305.60   | 3.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Genmab A/S                     | Genmab A/S                               | CUSIP: 372303206<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |    122429 | NS      | $3961802.44   | 3.78%             |  |  |  | No            |                  1 | On Loan: No      |
| Chugai Pharmaceutical Co Ltd   | Chugai Pharmaceutical Co Ltd             | CUSIP: N/A<br>LEI: 529900T9LAII161DCN95       | Long             | EC               | CORP              | JP        |     16512 | NS      | $885192.46    | 0.84%             |  |  |  | No            |                  1 | On Loan: No      |
| Celcuity Inc                   | Celcuity Inc                             | CUSIP: 15102K100<br>LEI: 25490070W7UU7W2SEY87 | Long             | EC               | CORP              | US        |     27170 | NS      | $2747973.80   | 2.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Janux Therapeutics Inc         | Janux Therapeutics Inc                   | CUSIP: 47103J105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     42511 | NS      | $1449199.99   | 1.38%             |  |  |  | No            |                  1 | On Loan: No      |
| ORIC Pharmaceuticals Inc       | ORIC Pharmaceuticals Inc                 | CUSIP: 68622P109<br>LEI: 54930033FJRNEYBW0L25 | Long             | EC               | CORP              | US        |     24617 | NS      | $292449.96    | 0.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc       | Revolution Medicines Inc                 | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |    101625 | NS      | $7902360.00   | 7.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Xencor Inc                     | Xencor Inc                               | CUSIP: 98401F105<br>LEI: 549300V5IF65437JKG30 | Long             | EC               | CORP              | US        |     53398 | NS      | $924853.36    | 0.88%             |  |  |  | No            |                  1 | On Loan: No      |
| Ideaya Biosciences Inc         | Ideaya Biosciences Inc                   | CUSIP: 45166A102<br>LEI: 549300ULW08F62IJML11 | Long             | EC               | CORP              | US        |     78259 | NS      | $2787585.58   | 2.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunome Inc                   | Immunome Inc                             | CUSIP: 45257U108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     85272 | NS      | $1570710.24   | 1.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvalent Inc                   | Nuvalent Inc                             | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     32207 | NS      | $3521835.45   | 3.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Nurix Therapeutics Inc         | Nurix Therapeutics Inc                   | CUSIP: 67080M103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     67655 | NS      | $1196140.40   | 1.14%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc            | Gilead Sciences Inc                      | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |     16560 | NS      | $2083910.40   | 1.99%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health Inc            | Guardant Health Inc                      | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |      7018 | NS      | $760891.56    | 0.73%             |  |  |  | No            |                  1 | On Loan: No      |
| HUTCHMED China Ltd             | HUTCHMED China Ltd                       | CUSIP: 44842L103<br>LEI: 2138006X34YDQ6OBYE79 | Long             | EC               | CORP              | HK        |     43149 | NS      | $622208.58    | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Pyxis Oncology Inc             | Pyxis Oncology Inc                       | CUSIP: 747324101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     41461 | NS      | $215182.59    | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Terns Pharmaceuticals Inc      | Terns Pharmaceuticals Inc                | CUSIP: 880881107<br>LEI: 254900S1ZDQMF4MYP709 | Long             | EC               | CORP              | US        |     14867 | NS      | $417911.37    | 0.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                 | Eli Lilly & Co                           | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |      5636 | NS      | $6061348.92   | 5.78%             |  |  |  | No            |                  1 | On Loan: No      |
| AnaptysBio Inc                 | AnaptysBio Inc                           | CUSIP: 032724106<br>LEI: 529900HH4WQT03IG1A12 | Long             | EC               | CORP              | US        |     19947 | NS      | $830792.55    | 0.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Olema Pharmaceuticals Inc      | Olema Pharmaceuticals Inc                | CUSIP: 68062P106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     39318 | NS      | $1113485.76   | 1.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Zymeworks Inc                  | Zymeworks Inc                            | CUSIP: 98985Y108<br>LEI: 894500AHOYAGYLYZJL67 | Long             | EC               | CORP              | US        |     67083 | NS      | $1791786.93   | 1.71%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                     | AbbVie Inc                               | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |     11054 | NS      | $2516995.80   | 2.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc           | Bridgebio Pharma Inc                     | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |     63618 | NS      | $4581132.18   | 4.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Exelixis Inc                   | Exelixis Inc                             | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |     67581 | NS      | $2985052.77   | 2.85%             |  |  |  | No            |                  1 | On Loan: No      |
| First American Treasury Obliga | First American Treasury Obligations Fund | CUSIP: 31846V328<br>LEI: 549300UU586IAH2B8H03 | Long             | STIV             | RF                | US        |   1672347 | NS      | $1672346.86   | 1.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Legend Biotech Corp            | Legend Biotech Corp                      | CUSIP: 52490G102<br>LEI: 254900EIUFZTW136H859 | Long             | EC               | CORP              | US        |     57468 | NS      | $1592438.28   | 1.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                      | Amgen Inc                                | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |      4653 | NS      | $1607425.38   | 1.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                      | Argenx SE                                | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |      1234 | NS      | $1125383.32   | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                | AstraZeneca PLC                          | CUSIP: N/A<br>LEI: PY6ZZQWO2IZFZC3IOL08       | Long             | EC               | CORP              | GB        |     22819 | NS      | $4220907.87   | 4.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Corvus Pharmaceuticals Inc     | Corvus Pharmaceuticals Inc               | CUSIP: 221015100<br>LEI: 549300I3AVJ8F75NCX65 | Long             | EC               | CORP              | US        |     62382 | NS      | $572042.94    | 0.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunocore Holdings PLC        | Immunocore Holdings PLC                  | CUSIP: 45258D105<br>LEI: 213800IUE3DFS84BVN18 | Long             | EC               | CORP              | GB        |     22510 | NS      | $889145.00    | 0.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc  | Regeneron Pharmaceuticals Inc            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      1898 | NS      | $1480800.62   | 1.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Replimune Group Inc            | Replimune Group Inc                      | CUSIP: 76029N106<br>LEI: 549300AY704NEIRC4K64 | Long             | EC               | CORP              | US        |     45276 | NS      | $452760.00    | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG               | Roche Holding AG                         | CUSIP: 771195104<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |     88084 | NS      | $4213057.72   | 4.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Schrodinger Inc/United States  | Schrodinger Inc/United States            | CUSIP: 80810D103<br>LEI: 984500044BAE4791E559 | Long             | EC               | CORP              | US        |     17733 | NS      | $311391.48    | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Summit Therapeutics Inc        | Summit Therapeutics Inc                  | CUSIP: 86627T108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     84589 | NS      | $1513297.21   | 1.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Zai Lab Ltd                    | Zai Lab Ltd                              | CUSIP: 98887Q104<br>LEI: 549300P2UYQ9U5LY1T58 | Long             | EC               | CORP              | CN        |     65397 | NS      | $1334752.77   | 1.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Daiichi Sankyo Co Ltd          | Daiichi Sankyo Co Ltd                    | CUSIP: N/A<br>LEI: 353800XGIU2IHQGC9504       | Long             | EC               | CORP              | JP        |     47476 | NS      | $1174400.72   | 1.12%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-01-21

**Name of Applicant:** Tema ETF Trust

**Signature:** /s/ Josh Hunter

**Name of Signer:** Josh Hunter

**Title:** Treasurer